The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD) and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their drug submission performance annual reports for the fiscal year 2020-2021 (from 1 April 2020 to 31 March 2021). The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical drug submission review activity, including average approval times.
The TPD, BRDD and NNHPD 2020-2021 reports also highlight significant events that occurred during Spring 2020 – such as the covid-19 pandemic – and include a section on applications under:
- the Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19;(1) and
- the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.(2)
For further information on this topic please contact Katie Lee at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smartbiggar.ca.
Endnotes
(1) For further information please see "Clinical trials relating to COVID-19".
(2) For further information please see "Health Canada facilitates availability of COVID-19 health products".